According to a StreetInsider report, Pfizer Inc. (NYSE:PFE) views Amarin Corporation plc (NasdaqGM:AMRN) and Vascepa as a good fit with its cardiovascular franchise and the Pfizer also has been looking for a potential blockbuster to replace its Lyrica nerve pain treatment before it goes off patent.